ALEXANDRIA, Va. / Nov 16, 2023 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced that Vincent D. Kelly, chief executive officer, will participate in the 35th annual Piper Sandler & Co. healthcare conference on November 29, 2023 in New York. The Company’s presentation is scheduled for 12:30 pm ET. Spok will also host a series of 1X1 meetings with investors on November 29, 2023.
The presentation will also be webcast and can be accessed via the conference presentation link, and in the investor relations section of the Company's website: http://www.spok.com.
About Spok
Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Alexandria, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication. For more information, visit spok.com.
Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.
| Last Trade: | US$13.90 |
| Daily Change: | 0.07 0.51 |
| Daily Volume: | 98,708 |
| Market Cap: | US$286.340M |
October 29, 2025 July 30, 2025 April 30, 2025 February 26, 2025 October 30, 2024 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load